Clinical features of infants hospitalized for 2009 pandemic influenza A (H1N1) in Japan: analysis using a national hospital discharge database

Pediatr Infect Dis J. 2012 Apr;31(4):368-72. doi: 10.1097/INF.0b013e318241ad06.

Abstract

Background: Earlier studies reported that infants <12 months of age were at high risk of hospitalization for 2009 pandemic influenza A H1N1 virus (2009 H1N1) infection, but there was little information about the clinical courses in these patients.

Methods: A retrospective study was performed using the nationwide inpatient Diagnosis Procedure Combination Database in Japan. We searched data on hospitalizations, between July and December 2009, of infants (<12 months) and children 12 to <24 months of age with influenza. We examined their demographic data and hospitalization details, including treatment, complications, and outcomes.

Results: During the study period, 1023 infants were hospitalized for influenza; 98.1% of them were previously healthy. Complications attributed to influenza were found in 181 (17.7%) infants, including 3 critical illnesses and 1 death. Oseltamivir was prescribed to 535 (53.3%) infants. We found no evidence that oseltamivir was associated with either complications or length of hospital stay. During the same period, 579 children 1 year of age were admitted for 2009 H1N1, and 56.5% of them had influenza-related complications.

Conclusions: In Japan, infants with 2009 H1N1 were twice as likely to be hospitalized as children 1 year of age. However, the clinical course of the hospitalized infants was generally uncomplicated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Antiviral Agents / administration & dosage
  • Female
  • Hospitals, Pediatric
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza A Virus, H1N1 Subtype / pathogenicity*
  • Influenza, Human / epidemiology*
  • Influenza, Human / pathology*
  • Influenza, Human / virology
  • Japan / epidemiology
  • Male
  • Oseltamivir / administration & dosage
  • Pandemics*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Oseltamivir